Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study

(2011) David Sullivan et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study

(2011) Tina Ken Schramm et al.   EUROPEAN HEART JOURNAL

Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study

(2011) Henriette Thisted Horsdal et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention - a retrospective nationwide cohort study

(2010) Casper H Jørgensen et al.   Cardiovascular Diabetology

Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

(2010) Hertzel C. Gerstein et al.   CIRCULATION

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes

(2010) Y. Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study

(2010) B. Sillars et al.   DIABETES OBESITY & METABOLISM

Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study

(2010) C. Andersson et al.   DIABETOLOGIA

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

(2010) T. Seck et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis

(2009) Kevin M. Pantalone et al.   ACTA DIABETOLOGICA

Rapid Identification of Myocardial Infarction Risk Associated With Diabetes Medications Using Electronic Medical Records

(2009) J. S. Brownstein et al.   DIABETES CARE

Thiazolidinediones and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus

(2009) Fei-Yuan Hsiao et al.   DRUG SAFETY

Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin

(2009) Colin R. Dormuth et al.   PLoS One

Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?: A meta-analysis of observational studies

(2008) A. D. Rao et al.   DIABETES CARE

Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: A matched case–control study

(2008) Shaukat M. Sadikot et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes

(2008) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Pioglitazone and Heart Failure: Results From a Controlled Study in Patients With Type 2 Diabetes Mellitus and Systolic Dysfunction

(2008) Thomas D. Giles et al.   JOURNAL OF CARDIAC FAILURE

Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007

(2008) Alexander M. Walker et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY